After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward

Gary Keblish, a schoolteacher treated in a late-stage trial of intismeran autogene, the mRNA cancer vaccine from Merck and Moderna, shared his story at the STAT Summit in Boston. Diagnosed with high-risk melanoma in 2019, he received the vaccine alongside Keytruda and described neuropathy during treatment. His tumor was removed six years ago and he continues teaching; the companies reported promising trial results in August.